Inventor · disambiguated record
David Proia
Also filed as: PROIA DAVID · PROIA DAVID A
8 granted patents·21 pending applications·22 citations·filing 2010–2023
80Inventor score
Files withSYNTA PHARMACEUTICALS CORP12PROIA DAVID7BLACKMAN RONALD K5MADRIGAL PHARMACEUTICALS INC2C4 THERAPEUTICS INC1
Top patents by PatentIndex Score
29 records- 0187US9439899B2Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitorsSYNTA PHARMACEUTICALS CORP·Filed 2012·Granted Sep 13, 2016·7 cites·17 claims
- 0282US11491145B2Combination therapies comprising targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2018·Granted Nov 8, 2022·1 cites·14 claims
- 0375US9205086B2Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitorBLACKMAN RONALD K·Filed 2011·Granted Dec 8, 2015·3 cites·3 claims
- 0473US8906885B2Treating cancer with HSP90 inhibitory compoundsEL-HARIRY IMAN·Filed 2012·Granted Dec 9, 2014·11 cites·23 claims
- 0570US2023046803A1Combination therapies comprising targeted therapeuticsMADRIGAL PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0662US2023190760A1Advantageous therapies for disorders mediated by ikaros or aiolosC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0754US11154538B2Combination therapy for treatment of ovarian cancerSYNTA PHARMACEUTICALS CORP·Filed 2017·Granted Oct 26, 2021·0 cites·7 claims
- 0849US10500193B2Combination therapy of HSP90 inhibitors with platinum-containing agentsSYNTA PHARMACEUTICALS CORP·Filed 2018·Granted Dec 10, 2019·0 cites·7 claims
- 0949US2016120849A1Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitorSYNTA PHARMACEUTICALS CORP·Filed 2015·Application pending·0 cites
- 1046US2014286902A1Combination therapy of hsp90 inhibitors with platinum-containing agentsSYNTA PHARMACEUTICALS CORP·Filed 2012·Application pending·0 cites
- 1145US2014051664A1Combination therapy of hsp90 inhibitory compounds with radiotherapyFOLEY KEVIN P·Filed 2012·Application pending·0 cites
- 1245US2017340652A1Combination therapy of hsp90 inhibitory compounds with chk inhibitorsSYNTA PHARMACEUTICALS CORP·Filed 2017·Application pending·0 cites
- 1344US11497733B2Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancerSYNTA PHARMACEUTICALS CORP·Filed 2016·Granted Nov 15, 2022·0 cites·13 claims
- 1444US2015150850A1Treating cancer with hsp90 inhibitory compoundsSYNTA PHARMACEUTICALS CORP·Filed 2014·Application pending·0 cites
- 1544US2014296176A1Combination cancer therapy with an hsp90 inhibitor and an antimetabolitePROIA DAVID·Filed 2012·Application pending·0 cites
- 1642US2015283147A1Treating polycystic kidney disease with hsp90 inhibitory compoundsSYNTA PHARMACEUTICALS CORP·Filed 2013·Application pending·0 cites
- 1742US2014005145A1Combination breast cancer therapy with hsp90 inhibitory compoundsPROIA DAVID·Filed 2011·Application pending·0 cites
- 1842US2013331357A1Combination therapy of hsp90 inhibitory compounds with proteasome inhibitorsPROIA DAVID·Filed 2012·Application pending·0 cites
- 1941US2014194388A1Combination therapy of hsp90 inhibitory compounds with chk inhibitorsPROIA DAVID·Filed 2012·Application pending·0 cites
- 2037US9402831B2Combination therapy of HSP90 inhibitors with BRAF inhibitorsSYNTA PHARMACEUTICALS CORP·Filed 2012·Granted Aug 2, 2016·0 cites·18 claims
- 2136US2013156755A1Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitorBLACKMAN RONALD K·Filed 2011·Application pending·0 cites
- 2232US2014228418A1Combination therapy of hsp90 inhibitory compounds with mek inhibitorsPROIA DAVID·Filed 2012·Application pending·0 cites
- 2331US2014051665A1Prostate cancer therapy with hsp90 inhibitory compoundsPROIA DAVID·Filed 2012·Application pending·0 cites
- 2431US2014045908A1Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancersBLACKMAN RONALD K·Filed 2012·Application pending·0 cites
- 2529US2013171105A1Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitorBLACKMAN RONALD K·Filed 2011·Application pending·0 cites
- 2628US2012245186A1Combination cancer therapy with hsp90 inhibitory compoundsBLACKMAN RONALD K·Filed 2010·Application pending·0 cites
- 2728US2016324863A1Targeted cancer treatment by hsp90 inhibitors ganetespib and nvp-auy922SYNTA PHARMACEUTICALS CORP·Filed 2015·Application pending·0 cites
- 2828US2015099721A1Treating cancer with hsp90 inhibitory compoundsSYNTA PHARMACEUTICALS CORP·Filed 2013·Application pending·0 cites
- 2926US2014315943A1Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitorsPROIA DAVID·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Proia files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →